These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 12714157

  • 21. Thrombin generation assay and viscoelastic coagulation monitors demonstrate differences in the mode of thrombin inhibition between unfractionated heparin and bivalirudin.
    Tanaka KA, Szlam F, Sun HY, Taketomi T, Levy JH.
    Anesth Analg; 2007 Oct; 105(4):933-9, table of contents. PubMed ID: 17898368
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Rotational thrombelastometry for the bedside monitoring of recombinant hirudin.
    Sucker C, Zotz RB, Görlinger K, Hartmann M.
    Acta Anaesthesiol Scand; 2008 Mar; 52(3):358-62. PubMed ID: 18205897
    [Abstract] [Full Text] [Related]

  • 29. Argatroban, bivalirudin, and lepirudin do not decrease clot propagation and strength as effectively as heparin-activated antithrombin in vitro.
    Nielsen VG, Steenwyk BL, Gurley WQ, Pereira SJ, Lell WA, Kirklin JK.
    J Heart Lung Transplant; 2006 Jun; 25(6):653-63. PubMed ID: 16730571
    [Abstract] [Full Text] [Related]

  • 30. Monitoring of recombinant hirudin: assessment of a plasma-based ecarin clotting time assay.
    Pötzsch B, Hund S, Madlener K, Unkrig C, Müller-Berghaus G.
    Thromb Res; 1997 Jun 01; 86(5):373-83. PubMed ID: 9211628
    [Abstract] [Full Text] [Related]

  • 31. Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial).
    Lincoff AM, Bittl JA, Kleiman NS, Sarembock IJ, Jackman JD, Mehta S, Tannenbaum MA, Niederman AL, Bachinsky WB, Tift-Mann J, Parker HG, Kereiakes DJ, Harrington RA, Feit F, Maierson ES, Chew DP, Topol EJ, REPLACE-1 Investigators.
    Am J Cardiol; 2004 May 01; 93(9):1092-6. PubMed ID: 15110198
    [Abstract] [Full Text] [Related]

  • 32. Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose, and gender.
    Robson R, White H, Aylward P, Frampton C.
    Clin Pharmacol Ther; 2002 Jun 01; 71(6):433-9. PubMed ID: 12087346
    [Abstract] [Full Text] [Related]

  • 33. Bivalirudin: a review of its potential place in the management of acute coronary syndromes.
    Carswell CI, Plosker GL.
    Drugs; 2002 Jun 01; 62(5):841-70. PubMed ID: 11929334
    [Abstract] [Full Text] [Related]

  • 34. [Experience with anticoagulation with bivalirudin during extracorporeal membrane oxygenation].
    Van Sint Jan N, Díaz R, Fajardo C, Agliatti R, Palavecino M, Hasbún P, Regueira T.
    Rev Med Chil; 2017 Jun 01; 145(6):710-715. PubMed ID: 29171618
    [No Abstract] [Full Text] [Related]

  • 35. Monitoring of anticoagulant effects of direct thrombin inhibitors.
    Fenyvesi T, Jörg I, Harenberg J.
    Semin Thromb Hemost; 2002 Aug 01; 28(4):361-8. PubMed ID: 12244483
    [Abstract] [Full Text] [Related]

  • 36. Effects of lepirudin, argatroban and melagatran and additional influence of phenprocoumon on ecarin clotting time.
    Fenyvesi T, Jörg I, Weiss C, Harenberg J.
    Thromb Res; 2003 Aug 01; 111(1-2):89-94. PubMed ID: 14644085
    [Abstract] [Full Text] [Related]

  • 37. Bivalirudin in acute coronary syndromes.
    Bonvini RF, Verin V, Righini M.
    N Engl J Med; 2007 Mar 08; 356(10):1070; author reply 1070-1. PubMed ID: 17354307
    [No Abstract] [Full Text] [Related]

  • 38. Bivalirudin in acute coronary syndromes.
    Sanmartin M.
    N Engl J Med; 2007 Mar 08; 356(10):1069-70; author reply 1070-1. PubMed ID: 17347463
    [No Abstract] [Full Text] [Related]

  • 39. Lepirudin dose-dependently increases thrombelastography parameters at therapeutic plasma concentrations as measured with ROTEM® - a pilot study.
    Feuring M, Wehling M, Schultz A.
    Int J Clin Pharmacol Ther; 2011 Oct 08; 49(10):626-8. PubMed ID: 21961488
    [Abstract] [Full Text] [Related]

  • 40. Bleeding risk and outcomes of Bivalirudin versus Glycoprotein IIb/IIIa inhibitors with targeted low-dose unfractionated Heparin in patients having percutaneous coronary intervention for either stable or unstable angina pectoris.
    Steinberg DH, Shah P, Kinnaird T, Pinto Slottow TL, Roy PK, Okabe T, Bonello L, de Labriolle A, Smith KA, Torguson R, Xue Z, Suddath WO, Kent KM, Satler LF, Pichard AD, Lindsay J, Waksman R.
    Am J Cardiol; 2008 Jul 15; 102(2):160-4. PubMed ID: 18602514
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.